BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO
May 09, 2024 at 07:00 am
Share
BioCryst Pharmaceuticals, Inc. announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR), which was held in Atlanta from May 5-8, 2024. Reductions in Real-World Healthcare Resource Utilization Among United States Hereditary Angioedema (HAE) Patients Following Berotralstat Initiation (Poster #EE477). The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States. The analysis focused on eligible patients who initiated ORLADEYO between December 2020 and December 2022 who had a baseline of a minimum of six months of continuous health plan enrollment prior to starting ORLADEYO, including commercial and public health plans. In addition to the overall study population (n=260), results were stratified by two subgroups: patients who had a history of being treated with HAE long-term prophylaxis (LTP) (n=126) and patients who were naïve to LTP but had a history of receiving on-demand treatment (n=67). Average (median) follow-up duration was 12 (13) months for the overall study population, 13 (13) months for LTP treatment-experienced patients, and 13 (14) for LTP treatment-naïve patients with prior on-demand treatment. Significant reductions in HRU were observed in the overall study population following initiation of ORLADEYO (p<0.05), including in: All-cause hospitalizations (34 percent reduction) and outpatient or emergency room visits (14% reduction), Angioedema-related hospitalizations (52% reduction) and outpatient or emergency room visits (44% reduction), Significant reductions were also observed in both subgroups (p<0.05), including in: Angioedema-related hospitalizations (54% reduction) and outpatient or emergency room visits (37%reduction) among LTP-experienced patients
Angioedema-related hospitalizations (62% reduction) and outpatient or emergency room visits (45% reduction) among LTP-naïve patients with a history of receiving on-demand treatment.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO